Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.38 |
| ▸ | CAMKK1 | Q8N5S9 | 2/20 | 0.32 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 3/20 | 0.31 |
| ▸ | ASPH | Q12797 | 1/20 | 0.31 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566926 | 1.00 | DGAT1 (0.38) | DGAT1CAMKK1CAMKK2RORCHRH2 | |
| SCHEMBL10099309 | 0.83 | CHRNA7 (0.36) | DGAT1 | |
| SCHEMBL565566 | 0.83 | GRM2 (0.35) | DGAT1 | |
| SCHEMBL566635 | 0.83 | GRM2 (0.35) | DGAT1 | |
| SCHEMBL10099139 | 0.79 | SCN9A (0.42) | — | |
| SCHEMBL567231 | 0.79 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL10099143 | 0.77 | SCN9A (0.40) | — | |
| SCHEMBL10099319 | 0.76 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL630837 | 0.75 | MTOR (0.33) | — | |
| SCHEMBL10099138 | 0.75 | JAK2 (0.33) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | DGAT1 4419/4885CAMKK1 1064/4885CAMKK2 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.